Want to join the conversation?
$REGN and $SNY closed enrollment in global Phase 3 Odyssey Outcomes Trial, which is prospectively evaluating potential cardiovascular (CV) benefits of Praluent (alirocumab) Injection after acute coronary syndrome (ACS). The 18,000-patient trial is seen to be closed in 2017. Praluent is now approved in the U.S. and EU to reduce bad cholesterol.
$MON shares dip slightly; I wonder this is because of the environmental lawsuit filed by the Washington state against the production of PCBs.
My bet is that $FR will reach $32 in the short term. It’s time it broke the 52-week high and had its fair share of growth.
$WYNN got bruised up by China after its decision to cut withdrawal limit in Macau ATMs. Wynn Resorts shares went down by more than 11%! Well who could have guessed that right?